Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23291787 | 0.87 | CSNK1A1 (0.40) | CYP11B2CYP11B1CSNK1A1CLK4TRPV4 | |
| SCHEMBL3825639 | 0.77 | CYP11B2 (0.39) | CYP11B2CYP11B1CSNK1A1CLK4TRPV4 | |
| SCHEMBL2761020 | 0.77 | CYP11B2 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL2931936 | 0.77 | CSNK1A1 (0.34) | CYP11B2CYP11B1CSNK1A1CLK4KMT2A | |
| SCHEMBL14157718 | 0.77 | ALDH1A1 (0.37) | CYP11B2CYP11B1CSNK1A1CLK4KMT2A | |
| SCHEMBL1215960 | 0.77 | CYP11B2 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL2935461 | 0.77 | CSNK1A1 (0.34) | CYP11B2CYP11B1CSNK1A1CLK4KMT2A | |
| SCHEMBL3660185 | 0.74 | CYP11B2 (0.40) | CYP11B2CYP11B1 | |
| SCHEMBL1922370 | 0.74 | PRKCQ (0.39) | CYP11B2CYP11B1 | |
| SCHEMBL4072210 | 0.73 | CYP11B2 (0.33) | CYP11B2CYP11B1CSNK1A1CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431345-A | Compound for regulating 15-PGDH activity and preparation method thereof | 赛诺哈勃药业（成都）有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2021063207-A1 | JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-04-08 | — | — | WO | disclosed |
| CN-112574123-A | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| CN-101137643-A | Novel pyridine compounds | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-6197964-B1 | CHLORINATION USING BASIC CATALYST; DESALTING, HYDROLYSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0973745-A1 | METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORONICOTINONITRILE AND THE CHEMICAL COMPOUND 3-CYANO-2-HYDROXY-5-FLUOROPYRIDE-6-ONE-MONOSODIUM SALT AND ITS TAUTOMERS | BAYER AG (DE) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043958-A1 | METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORONICOTINONITRILE AND THE CHEMICAL COMPOUND 3-CYANO-2-HYDROXY-5-FLUOROPYRIDE-6-ONE-MONOSODIUM SALT AND ITS TAUTOMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CYP11B2 1/4885CYP11B1 2/4885CSNK1A1 253/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CYP11B2 1/4885CYP11B1 2/4885CSNK1A1 253/4885 |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | CYP11B2 1011/4885CYP11B1 1248/4885CSNK1A1 1194/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | CYP11B2 1656/4885CYP11B1 1619/4885CSNK1A1 821/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CYP11B2 1/4885CYP11B1 2/4885CSNK1A1 253/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | CYP11B2 274/4885CYP11B1 513/4885CSNK1A1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.